These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 15626743)

  • 1. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
    Orlowski RZ; Voorhees PM; Garcia RA; Hall MD; Kudrik FJ; Allred T; Johri AR; Jones PE; Ivanova A; Van Deventer HW; Gabriel DA; Shea TC; Mitchell BS; Adams J; Esseltine DL; Trehu EG; Green M; Lehman MJ; Natoli S; Collins JM; Lindley CM; Dees EC
    Blood; 2005 Apr; 105(8):3058-65. PubMed ID: 15626743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
    Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
    LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
    Jakubowiak AJ; Griffith KA; Reece DE; Hofmeister CC; Lonial S; Zimmerman TM; Campagnaro EL; Schlossman RL; Laubach JP; Raje NS; Anderson T; Mietzel MA; Harvey CK; Wear SM; Barrickman JC; Tendler CL; Esseltine DL; Kelley SL; Kaminski MS; Anderson KC; Richardson PG
    Blood; 2011 Jul; 118(3):535-43. PubMed ID: 21596852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
    Holkova B; Perkins EB; Ramakrishnan V; Tombes MB; Shrader E; Talreja N; Wellons MD; Hogan KT; Roodman GD; Coppola D; Kang L; Dawson J; Stuart RK; Peer C; Figg WD; Kolla S; Doyle A; Wright J; Sullivan DM; Roberts JD; Grant S
    Clin Cancer Res; 2011 May; 17(10):3388-97. PubMed ID: 21447728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
    Holkova B; Kmieciak M; Perkins EB; Bose P; Baz RC; Roodman GD; Stuart RK; Ramakrishnan V; Wan W; Peer CJ; Dawson J; Kang L; Honeycutt C; Tombes MB; Shrader E; Weir-Wiggins C; Wellons M; Sankala H; Hogan KT; Colevas AD; Doyle LA; Figg WD; Coppola D; Roberts JD; Sullivan D; Grant S
    Clin Cancer Res; 2014 Nov; 20(22):5652-62. PubMed ID: 25248382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
    J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
    Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F
    Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
    Lee J; Suh C; Kang HJ; Ryoo BY; Huh J; Ko YH; Eom HS; Kim K; Park K; Kim WS
    Ann Oncol; 2008 Dec; 19(12):2079-83. PubMed ID: 18689866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
    Reece DE; Sullivan D; Lonial S; Mohrbacher AF; Chatta G; Shustik C; Burris H; Venkatakrishnan K; Neuwirth R; Riordan WJ; Karol M; von Moltke LL; Acharya M; Zannikos P; Keith Stewart A
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):57-67. PubMed ID: 20306195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
    Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
    Schwartz R; Davidson T
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
    Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
    Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
    Orlowski RZ; Stinchcombe TE; Mitchell BS; Shea TC; Baldwin AS; Stahl S; Adams J; Esseltine DL; Elliott PJ; Pien CS; Guerciolini R; Anderson JK; Depcik-Smith ND; Bhagat R; Lehman MJ; Novick SC; O'Connor OA; Soignet SL
    J Clin Oncol; 2002 Nov; 20(22):4420-7. PubMed ID: 12431963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
    Falchook GS; Duvic M; Hong DS; Wheler J; Naing A; Lim J; Kurzrock R
    Cancer Chemother Pharmacol; 2012 May; 69(5):1117-26. PubMed ID: 22205203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
    Awada A; Albanell J; Canney PA; Dirix LY; Gil T; Cardoso F; Gascon P; Piccart MJ; Baselga J
    Br J Cancer; 2008 May; 98(9):1500-7. PubMed ID: 18454159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
    Lancet JE; Duong VH; Winton EF; Stuart RK; Burton M; Zhang S; Cubitt C; Blaskovich MA; Wright JJ; Sebti S; Sullivan DM
    Clin Cancer Res; 2011 Mar; 17(5):1140-6. PubMed ID: 21233404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
    Ogawa Y; Tobinai K; Ogura M; Ando K; Tsuchiya T; Kobayashi Y; Watanabe T; Maruyama D; Morishima Y; Kagami Y; Taji H; Minami H; Itoh K; Nakata M; Hotta T
    Cancer Sci; 2008 Jan; 99(1):140-4. PubMed ID: 17970782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.